IN8bio to Present at 2024 European Hematology Association Congress
NEW YORK, May 14, 2024 — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta T cell therapies, has announced a presentation at the European Hematology Association (EHA) 2024 Congress, scheduled for June 13-16 in Madrid, Spain.
Trishna Goswami, M.D., Chief Medical Officer at IN8bio, expressed enthusiasm for sharing the latest interim results from their Phase 1 trial of the gamma-delta T cell therapy INB-100. This therapy is being evaluated following haploidentical stem cell transplantation in patients with leukemia. "The data so far indicates that our approach could potentially improve survival rates and reduce cancer recurrence in adults diagnosed with or relapsed forms of Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), or Myelodysplastic Syndromes (MDS), without inducing severe graft-versus-host disease. We are eager to present more details and the progress we've made, with the hope of broadening current treatment options for cancer patients," said Dr. Goswami.
Details of the poster presentation are as follows:
- Title: INB-100: Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-delta T Cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide
- Presentation Date/Time: Friday, June 14, 2024, at 10:00 a.m. CEST
- Submission ID: EHA-2057
- Poster Session: P1460
- Abstract Topic: Gene therapy, cellular immunotherapy and vaccination – Clinical
- Presenter: Dr. Joseph P. McGuirk, M.D., Schutte-Speas Professor of Hematology-Oncology, Division Director of Hematologic Malignancies and Cellular Therapeutics, Medical Director of Blood and Marrow Transplant at The University of Kansas Cancer Center
Abstracts can be accessed through the European Hematology Association's website. A copy of the poster presentation will be available on the IN8bio website following the session.
IN8bio is dedicated to developing gamma-delta T cell-based immunotherapies to treat cancer patients. Gamma-delta T cells are a distinct subset of T cells capable of distinguishing between healthy and diseased tissues. Their lead program, INB-400, is currently in a Phase 2 trial targeting glioblastoma multiforme (GBM). Other programs include Phase 1 trials for both solid and hematologic tumors, such as INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation.
IN8bio, Inc. is at the forefront of developing transformative therapies using gamma-delta T cells, aiming to offer new hope for patients battling various forms of cancer. Their pioneering approaches in immunotherapy hold promise for improving patient outcomes significantly.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
